glp-1 prescriptions growth slowing 2024 Are Up, Health Services Utilization Down, and GLP-1s Are a Major Driver: IQVIA's Update GLP-1 Prescribing Is Rising —
Description
Status tracking and follow-up
Safety is evaluated through method, not noise.
FDA-approved candidates include adults with BMI 30 kg/m or BMI 27 kg/m with weight-related comorbidities such as hypertension, dyslipidemia, or cardiovascular disease
3
A real day for a 200 lb adult on a moderate deficit, hitting roughly 150 g protein on 1,800 calories
